Form 8-K - Current report:
SEC Accession No. 0001193125-24-141703
Filing Date
2024-05-17
Accepted
2024-05-17 16:02:01
Documents
14
Period of Report
2024-05-16
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d829869d8k.htm   iXBRL 8-K 46237
2 EX-99.1 d829869dex991.htm EX-99.1 125623
  Complete submission text file 0001193125-24-141703.txt   331640

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rgls-20240516.xsd EX-101.SCH 2857
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rgls-20240516_lab.xml EX-101.LAB 17995
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rgls-20240516_pre.xml EX-101.PRE 11266
17 EXTRACTED XBRL INSTANCE DOCUMENT d829869d8k_htm.xml XML 3645
Mailing Address 4224 CAMPUS POINT COURT SUITE 210 SAN DIEGO CA 92121
Business Address 4224 CAMPUS POINT COURT SUITE 210 SAN DIEGO CA 92121 858-202-6300
Regulus Therapeutics Inc. (Filer) CIK: 0001505512 (see all company filings)

IRS No.: 264738379 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35670 | Film No.: 24959450
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)